Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin in obese adults with COPD and impaired glucose tolerance or diet-controlled type 2 diabetes
ACTRN12610000378022Phase 2Completed
- Sponsor
- Dr Paul Sexton
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of metformin in chronic obstructive pulmonary disease (COPD), type 2 diabetes mellitus (T2DM), prediabetes and 1 more, sponsored by Dr Paul Sexton. Primary endpoint: Change in forced expiratory volume in first second (FEV1) at 24 weeks. Started Jun 2011; status: completed.
02
Drugs
metformin
03
Conditions
chronic obstructive pulmonary disease (COPD)type 2 diabetes mellitus (T2DM)prediabetesinsulin resistance (IR)
Beyond the preview
Go deeper on ACTRN12610000378022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000378022.